Evidence map›Paper›PMID 33778011›Full record

ArticleFrontiers in molecular biosciences2021

Cell Division Cycle Associated Genes as Diagnostic and Prognostic Biomarkers in Hepatocellular Carcinoma.

Shan-Shan Jiang, Sheng-Jie Ke, Zun-Li Ke, Juan Li, Xiang Li, Xing-Wei Xie

Open access · goldAbstract read
In one paragraph

Article in Frontiers in molecular biosciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Shan-Shan JiangKey Laboratory of Forensic Toxicology of Herbal Medicines, Guizhou Education Department, School of Basic Medicine, Guizhou University of Traditional Chinese Medicine, Guiyang, China.
Sheng-Jie KeFaculty of Basic Medicine, Zhengzhou Shuqing Medical College, Henan, China.
Zun-Li KeKey Laboratory of Forensic Toxicology of Herbal Medicines, Guizhou Education Department, School of Basic Medicine, Guizhou University of Traditional Chinese Medicine, Guiyang, China.
Juan LiKey Laboratory of Forensic Toxicology of Herbal Medicines, Guizhou Education Department, School of Basic Medicine, Guizhou University of Traditional Chinese Medicine, Guiyang, China.
Xiang LiCollege of Plant Protection, Henan Agricultural University, Zhengzhou, China.
Xing-Wei XieKey Laboratory of Forensic Toxicology of Herbal Medicines, Guizhou Education Department, School of Basic Medicine, Guizhou University of Traditional Chinese Medicine, Guiyang, China.
Guiyang College of Traditional Chinese Medicine · CNHenan Agricultural University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With high mortality and poor prognosis, hepatocellular carcinoma (LIHC) has become the fourth leading cause of cancer-related deaths worldwide. Most of the LIHC patients missed the best treatment period because of the untimely diagnosis. For others, even if they are temporarily cured, they have to face a very low prognostic survival rate and a very high risk of recurrence. Based on the characteristics of abnormal proliferation and uncontrolled growth of tumor cells. Cell Division Cycle Associated (

Indexed as

biomarkersCDCAhepatocellular carcinomaprognosistumor immunity

Identifiers

PMID33778011
PMCPMC7991583
OpenAlexW3135736519

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.